ProCE Banner Activity

NSABP FB-7: Dual HER2-Targeted Therapy in HER2+ Locally Advanced Breast Cancer

Slideset Download
Conference Coverage
In this phase II trial, the use of paclitaxel with neratinib plus trastuzumab increased pCR rate vs paclitaxel and either anti-HER2 agent alone in women with HER2+ locally advanced breast cancer.

Released: December 13, 2015

Expiration: December 11, 2016

No longer available for credit.

Share

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech BioOncology

Novartis Pharmaceuticals Corporation